Skip to main content
ADCT
NYSE Life Sciences

ADC Therapeutics Q3 Revenue Jumps to $21.0M, Cash Runway Extended Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.746
Mkt Cap
$201.715M
52W Low
$0.78
52W High
$4.98
52W Position info
124% above low
Off High info
65% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ADCT has more than doubled off its 52-week low of $0.78.

Summary

ADC Therapeutics posted Q3 product revenue of $21.0M (up from $15.8M) and narrowed its net loss to $25.3M, with $189.2M in cash supporting a runway into 2029. Japan partner Tanabe filed a marketing application for ZYNLONTA, and full LOTIS-5 data is set for ASH in December.


Key Events · Earnings and Guidance · ADCT

  • Q3 Product Revenue Grows 33%

    Net product revenue was $21.0M versus $15.8M a year ago, driven by higher volume; nine-month product revenue reached $59.7M versus $51.2M.

  • Net Loss Narrowed Sharply

    Q3 net loss fell to $25.3M ($0.16 per share) from $41.0M ($0.30 per share); adjusted net loss was $8.8M ($0.06 per share) versus $25.5M ($0.19).

  • Cash Runway Extended Into 2029

    Cash and equivalents stood at $189.2M at September 30, 2026, down from $261.3M at year-end 2025, with runway projected into 2029 following the October restructuring.

  • Japan Filing and Sublicense

    Tanabe Pharma submitted a marketing authorization application for ZYNLONTA in relapsed/refractory DLBCL to Japan's Ministry of Health and signed an exclusive sublicensing deal with Nippon Shinyaku for Japanese commercialization.


Analysis · ADCT · Life Sciences

Product revenue grew 33% year over year to $21.0M while operating expenses fell 24%, cutting the quarterly net loss to $25.3M from $41.0M. With $189.2M in cash after the October restructuring, management now projects funding into 2029 — removing near-term financing risk for a company whose balance sheet previously carried a $303.5M deferred royalty obligation and $116.1M of term loans. The remaining overhang is regulatory: the FDA's previously disclosed concerns about LOTIS-5 still govern whether ZYNLONTA keeps full approval, and the full LOTIS-5 data will be presented at ASH in December.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADCT was trading at $1.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $201.7M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADCT - Latest Insights

ADCT
Nov 09, 2026, 7:30 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.71 info
Change: +$0.130 (+8%) info
Market Cap: $201.715M info
ADCT
Nov 04, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.71 info
Change: -$0.010 (-0.58%) info
Market Cap: $201.715M info
ADCT
Nov 03, 2026, 5:02 PM EST
Filing Type: S-4
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.71 info
Change: +$0.160 (+10%) info
Market Cap: $201.715M info
ADCT
Oct 13, 2026, 6:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $1.71 info
Change: -$0.110 (-6%) info
Market Cap: $201.715M info
ADCT
Oct 08, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $1.71 info
Change: +$0.380 (+29%) info
Market Cap: $201.715M info